Comment on FR Doc # 2026-10128

I am submitting this comment because I believe there is a serious and growing problem with the consistency, quality, and effectiveness of prescription amphetamine medications, particularly Adderall XR, that deserves meaningful regulatory scrutiny. I have taken prescription Adderall XR for more than 17 years. For most of that time, I knew exactly what to expect from my medication. It worked reliably, allowed me to focus, helped me stay awake and mentally engaged, and provided therapeutic coverage throughout my day. I was able to read, work, complete tasks, and function normally. In 2024, I was able to read 68 books. That is how dramatically my ability to focus and engage with life has changed since my medication stopped working as it once did. Today, the medication I receive is not remotely comparable to what I took for many years. I have experienced a dramatic decline in effectiveness, duration, and consistency. Medication that previously provided approximately 8–10 hours of meaningful therapeutic benefit may now provide little benefit at all or wear off after only a few hours. Instead of feeling focused and functional, I have experienced fatigue, brain fog, excessive yawning, headaches, eye pressure, and an inability to concentrate. I want to be clear: I am not asking for a higher dose. I am asking for the medication prescribed to me to consistently contain and deliver the therapeutic effect that patients and physicians reasonably expect from the labeled product. I have changed manufacturers, tried different formulations, consulted additional medical professionals, and changed medications because the product I once relied upon no longer works the same way. These changes have disrupted my treatment, my ability to work, my ability to read, and my quality of life. I have spent significant time and money trying to determine whether the problem was me, my health, tolerance, or the medication itself. What concerns me most is that I am far from the only patient reporting this experience. There are widespread reports from patients describing amphetamine products as weaker, shorter-acting, inconsistent, or substantially different from the medications they previously received. While individual patient response can certainly vary, the sheer number of similar reports should not be dismissed automatically as tolerance, placebo effects, or patients simply wanting higher doses. Patients with ADHD should not have to become pharmaceutical investigators just to determine why a medication that worked for years suddenly no longer works. We should not have to change pharmacies repeatedly, search for specific manufacturers, compare tablets and capsules, seek multiple medical opinions, or repeatedly change treatment plans because of unexplained differences in medication effectiveness. I respectfully urge the DEA and other appropriate regulatory agencies to investigate whether changes in manufacturing processes, active pharmaceutical ingredient sourcing, formulation, allowable variability, production constraints, or other factors may be contributing to the widespread perception that prescription amphetamine medications are no longer consistently delivering the therapeutic effect patients previously experienced. I also urge regulators to consider independent, random testing of prescription amphetamine products from different manufacturers and production lots. A medication labeled as a specific dose should not merely meet a theoretical standard on paper; it should reliably deliver a consistent therapeutic product to the patients who depend on it. For many patients, these medications are not optional lifestyle products. They determine whether we can work, read, complete basic responsibilities, and participate fully in our own lives. When the medication suddenly becomes ineffective, the consequences are significant. I am asking the DEA to take patient reports seriously and to investigate this issue rather than assuming that every report of dramatically reduced effectiveness is simply tolerance or individual variability. Patients deserve transparency, consistency, and confidence that the medication prescribed to them is manufactured to the same reliable standard over time. I am not asking for special treatment. I am asking for accountability and for the medication that I have depended on for nearly two decades to be consistently manufactured, accurately dosed, and therapeutically reliable.